-
公开(公告)号：EP3985022A1
公开(公告)日：2022-04-20
申请号：EP20822425.3
申请日：2020-06-15
申请人： ABL Bio, Inc.
发明人： AN, Sungwon , AHN, Jinhyung , SUNG, Byungje , KIM, Dongin , SONG, Daehae , EOM, Jaehyun , SON, Yong-Gyu , PARK, Kyungjin , KIM, Juhee , JUNG, Jinwon , LEE, Bora , YUN, Hyesu
摘要： The present disclosure relates to a bispecific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bispecific antibody for the prevention, treatment and / or diagnosis of synucleinopatheis associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.
-
公开(公告)号：EP4403218A2
公开(公告)日：2024-07-24
申请号：EP24170761.1
申请日：2018-12-14
申请人： ABL Bio, Inc.
发明人： AHN, Jinhyung , AN, Sungwon , KIM, Dongin , SUNG, Eunsil , EOM, Jaehyun , LEE, Sang Hoon , YOU, Weonkyoo , KIM, Juhee , PARK, Kyungjin , CHUNG, Hyejin , JUNG, Jinwon , LEE, Bora , SUNG, Byungje , KIM, Yeunju , SON, Yong-Gyu , AHN, Seawon , SONG, Daehae , YOO, Jiseon , PAK, Youngdon , YEOM, Donghoon , LEE, Yoseob , JUNG, Jaeho
IPC分类号： A61P25/00
CPC分类号： C07K16/2863 , C07K16/18 , C07K2317/3120130101 , C07K2317/9420130101 , C07K2317/9220130101 , C07K2317/7720130101 , A61P25/16 , C07K2317/2120130101 , C07K2317/2420130101 , C07K2317/3420130101 , C07K2317/3520130101 , C07K2317/52620130101 , C07K2317/56520130101 , C07K2317/62220130101 , C07K2317/3320130101 , A61K2039/50520130101 , A61P25/00
摘要： The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.
-
公开(公告)号：EP4340881A1
公开(公告)日：2024-03-27
申请号：EP22806958.9
申请日：2022-05-12
申请人： ABL Bio Inc.
发明人： PARK, Kyungjin , SONG, Daehae , JUNG, Jinwon , SUNG, Byungje , YUN, Hyesu , SHIN, Jung-Won , AN, Sungwon , KIM, Juhee , LEE, Bora , AHN, Jinhyung , KIM, Dongin , KIM, Donghwan , SON, Yong-Gyu , PAK, Youngdon
IPC分类号： A61K39/395 , A61P25/28 , C07K16/18
-
公开(公告)号：EP3725806A1
公开(公告)日：2020-10-21
申请号：EP18889608.8
申请日：2018-12-14
申请人： ABL Bio Inc.
发明人： AHN, Jinhyung , AN, Sungwon , KIM, Dongin , SUNG, Eunsil , EOM, Jaehyun , LEE, Sang Hoon , YOU, Weonkyoo , KIM, Juhee , PARK, Kyungjin , CHUNG, Hyejin , JUNG, Jinwon , LEE, Bora , SUNG, Byungje , KIM, Yeunju , SON, Yong-gyu , AHN, Seawon , SONG, Daehae , YOO, Jiseon , PAK, Youngdon , YEOM, Donghoon , LEE, Yoseob , JUNG, Jaeho
摘要： The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bi-specific antibody for the prevention, treatment and / or diagnosis of synucleinopatheis associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.
-
公开(公告)号：EP3725802A2
公开(公告)日：2020-10-21
申请号：EP18879299.8
申请日：2018-11-16
申请人： ABL Bio Inc.
发明人： LEE, Sang Hoon , YOU, Weonkyoo , AHN, Jinhyung , AN, Sungwon , JUNG, Jinwon , LEE, Bora , KIM, Dongin , SUNG, Byungje , SON, Yonggyu , KIM, Yeunju , EOM, Jaehyun , AHN, Seawon , PAK, Youngdon , YEOM, Donghoon , SONG, Daehae
摘要： The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody.
-
公开(公告)号：EP3567054A1
公开(公告)日：2019-11-13
申请号：EP18736765.1
申请日：2018-01-05
申请人： ABL Bio Inc.
发明人： AHN, Jinhyung , AN, Sungwon , KIM, Dongin , SUNG, Eunsil , EOM, Jaehyun , LEE, Sang Hoon , LEE, Seung-Jae , KIM, Tae Kyung , CHOI, Min Sun , YOU, Weonkyoo , JUNG, Jaeho , KIM, Juhee , JUNG, Jinwon , KIM, Yeunju , SON, Yonggyu , SUNG, Byungje
摘要： The disclosure discloses anti α-Syn antibodies preferentially recognizing α-Syn aggregates. The antibodies of the present invention bind to α-Syn aggregates with high affinity and specificity and inhibit accumulation or intercellular transfer of α-Syn aggregates, and thus can be used for detection, diagnosis and/or treatment or prevention of various diseases caused by the accumulation of α-Syn aggregates.
-
公开(公告)号：EP4403218A3
公开(公告)日：2024-11-06
申请号：EP24170761.1
申请日：2018-12-14
申请人： ABL Bio, Inc.
发明人： AHN, Jinhyung , AN, Sungwon , KIM, Dongin , SUNG, Eunsil , EOM, Jaehyun , LEE, Sang Hoon , YOU, Weonkyoo , KIM, Juhee , PARK, Kyungjin , CHUNG, Hyejin , JUNG, Jinwon , LEE, Bora , SUNG, Byungje , KIM, Yeunju , SON, Yong-Gyu , AHN, Seawon , SONG, Daehae , YOO, Jiseon , PAK, Youngdon , YEOM, Donghoon , LEE, Yoseob , JUNG, Jaeho
摘要： The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.
-
公开(公告)号：EP4268842A3
公开(公告)日：2024-05-22
申请号：EP23178097.4
申请日：2020-06-15
申请人： ABL Bio, Inc.
发明人： AN, Sungwon , AHN, Jinhyung , SUNG, Byungje , KIM, Dongin , SONG, Daehae , EOM, Jaehyun , SON, Yong-Gyu , PARK, Kyungjin , KIM, Juhee , JUNG, Jinwon , LEE, Bora , YUN, Hyesu
CPC分类号： A61P25/28 , C07K16/2863 , A61K2039/50520130101 , C07K2317/3120130101 , C07K2317/56520130101 , C07K2317/3320130101 , C07K2317/3420130101 , C07K2317/7720130101 , C07K2317/9220130101 , C07K2317/62220130101 , C07K16/2896 , C07K16/18
摘要： The present disclosure relates to a bispecific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bispecific antibody for the prevention, treatment and / or diagnosis of synucleinopatheis associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.
-
公开(公告)号：EP4268842A2
公开(公告)日：2023-11-01
申请号：EP23178097.4
申请日：2020-06-15
申请人： ABL Bio, Inc.
发明人： AN, Sungwon , AHN, Jinhyung , SUNG, Byungje , KIM, Dongin , SONG, Daehae , EOM, Jaehyun , SON, Yong-Gyu , PARK, Kyungjin , KIM, Juhee , JUNG, Jinwon , LEE, Bora , YUN, Hyesu
IPC分类号： A61K39/00
摘要： The present disclosure relates to a bispecific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bispecific antibody for the prevention, treatment and / or diagnosis of synucleinopatheis associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.013 秒)
